In the present study, we evaluated the effects of losartan on NAFLD in an obese model; there was no significant improvement in plasma ALT and AST, which is in line with the previous observation of Hirata and coworkers in NAFLD patients [23]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.